Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
Seventeen patients treated for a mean period of 9-4 months with an enteric-coated form of L-dopa (Prodopa), obtained the usual spectrum of benefit as from conventional L-dopa. There was a significant dose-sparing effect with the use of the enteric-coated prepartion of the order of 40% to 50%, whilst reducing gastrointestinal side effects to a minimum, at the same time as achieving optimal clinicl benefit. Enteric-coated L-dopa appears to be a useful and welcome addition to the therapeutic armamentarium for Parkinson's disease.